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A 66-year-old male treated with everolimus for renal cell carcinoma developed exertional dyspnea. Chest
computed tomography revealed diffuse interstitial shadows on both lungs. Bronchoalveolar lavage and
the drug-induced lymphocyte stimulation test conﬁrmed the diagnosis of drug-induced interstitial lung
disease due to everolimus therapy. However, discontinuation of everolimus in combination with corti-
costeroid therapy did not prevent disease progression. On the basis of a PCR assay for Pneumocystis
jirovecii and elevated b-D-glucan levels, trimethoprim-sulfamethoxazole was administered immediately,
resulting in a dramatic improvement. This case demonstrated that pneumocystis pneumonia should
always be considered and treated during everolimus therapy, even when drug-induced interstitial lung
disease is suspected.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Everolimus, an inhibitor of the mammalian target of rapamycin
(mTOR), is an effective antitumor drug for renal cell carcinomas
(RCCs), with its use increasing for management of other neoplasms
such as breast cancer [1], neuroendocrine tumors [2], and angio-
myolipoma [3]. Because of the high incidence of pulmonary adverse
effects caused by the drug, this increased use of everolimus is ex-
pected to result in an increased number of patients with drug-
induced interstitial lung disease (ILD). In fact, drug-induced ILD
was reported to occur in 13.5% patients receiving everolimus in a
phase III clinical trial for RCC [4]. In addition to its antitumor effects,
everolimus has been used as an immunosuppressant to prevent the
rejection of heart and kidney transplants [5]. Therefore, scrupulous
care must be taken against opportunistic infections whenever
everolimus is used; however, to our knowledge, there is only
limited information regarding pulmonary infectious complications
associated with everolimus therapy. In this paper we describe
a case of pneumocystis pneumonia (PCP), which was clinically1; fax: þ81 226 2176.
r Ltd. Open access under CC BY-NC-SAsimilar to everolimus-induced ILD and was initially managed
with a corticosteroid. The patient was successfully treated with
trimethoprim-sulfamethoxazole immediately after being diag-
nosed with PCP on the basis of a PCR assay for Pneumocystis jirovecii
and elevated b-D-glucan levels.
2. Case report
A 66-year-old Japanesemalewith advanced renal cell carcinoma
(RCC) visited our respiratory outpatient clinic complaining of pro-
gressive exertional dyspnea for 1 month after administration of
everolimus. He had suffered from unresectable RCC with multiple
bone metastases for 2 years (clear cell carcinoma. cT3cN0M1. stage
IV). Previous therapy included sunitinib for 1 year, followed by
axitinib for 2 months. This regimen failed to prevent disease pro-
gression. Thereafter, third-line therapy with everolimus was initi-
ated. The patient was an exsmoker and had stopped smoking 35
years back. Annual check-ups had revealed that he was asymp-
tomatic for any breathing problems, with no abnormalities in the
pulmonary function tests or chest computed tomography (CT)
scans. On his ﬁrst visit to our clinic, he was afebrile but presented
with general malaise and tachypnea accompanied by hypoxemia
(SpO2, 96% after inhaling oxygen by mask at 4 L/min). He had slight
systemic edema, probably caused by renal insufﬁciency and/or
hypoalbuminemia. Cardiac pulmonary edema was excluded by
echocardiography. On chest auscultation, no wheeze or crackle was license.
Table 1
Laboratory data on admission.
Hematology Biochemistry Serology
WBC 3200/uL TP 5.5 g/dL CRP 16.7m g/dL
Neutrophil 70.5% Alb 2.8 g/dL KL-6 735 U/mL
Lymphocyte 21.5% LDH 583 IU/L
Monocyte 5% AST 67 IU/L
Eosinophil 0% ALT 28 IU/L
Basophil 3% ALP 523 IU/L
RBC 405  104/uL BUN 35m g/dL
Hgb 10.2 g/dL Cre 1.66m g/dL
Hct 31% Na 134 mEq/L
Plt 26  104/uL K 3.8 mEq/L
Cl 94 mEq/L
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lungs, while chest CT revealed diffuse ground glass opacities in both
lung ﬁelds (Fig. 1A and B). The laboratory ﬁndings on admission are
presented in Table 1. In brief, we observedmild lymphocytosis, mild
anemia, thrombocytopenia, slight liver dysfunction, and renal
insufﬁciency. Lactate dehydrogenase (LDH) and CRP were elevated
at 583 IU/L and 16.7 mg/dl, respectively. The serum level of Krebs
von den Lungen-6 (KL-6): a sensitive marker for interstitial pneu-
monia, was also elevated at 735 U/mL (normal range; <500 U/mL),
excluding the possibility of atypical pneumonia. On the basis of
these ﬁndings, we suspected that the patient had everolimus-
induced ILD. On the ﬁrst hospital day, a bronchoalveolar lavage
(BAL) was performed to determine the cellular fractionation in the
BAL ﬂuid (BALF) as well as to exclude respiratory infections. BALF
recovered from right B3b revealed an increased total cell number
(3.10  105 cells/mL) with lymphocytosis (macrophages, 65.4%;
lymphocytes, 29.0%; neutrophils, 4.2%; eosinophils, 1.4%). The CD4/
CD8 ratio was 0.9 (normal range in nonsmokers, 0.41.0). BALF
cultures were negative for bacteria, acid-fast bacilli, and fungi.
Unfortunately, we could not perform a transbronchial lung biopsy
(TBLB) because of the patient’s frequent cough and oxygen desa-
turation during the bronchoscopic procedure.
Because drug allergy for everolimus was strongly suspected, we
performed a drug-induced lymphocyte stimulation test (DLST)
using serum and BALF. Although DLST with serum revealed a
negative reaction, the test with BALF was positive with a stimula-
tion index of 204% compared with that in the control (368 cpm for
everolimus and 179 cpm for control). Taken together, these clinical
ﬁndings conﬁrmed the diagnosis of everolimus-induced ILD.
Therefore, everolimus therapy was discontinued, and intravenous
methylprednisolone administration (1000 mg/day for 3 consecu-
tive days) was initiated immediately after BAL. Oral prednisolone
administration (50 mg/day) was followed by steroid pulse therapy.
Despite this vigorous therapy, his respiratory distress and radio-
graphic ﬁndings rapidly exacerbated day by day (Fig. 2). On the ﬁfth
hospital day, the presence of PCR for Pneumocystis jirovecii DNA in
BALF was established. Moreover, serum (1e3) e bD-glucan levels
were markedly increased at 137.5 pg/mL (normal range; <20 pg/
mL). Cytomegalovirus (CMV) pp65 antigenemia in the serum and
CMV-DNA in BALF were negative. Therefore, a diagnosis of PCP was
conﬁrmed. Intravenous trimethoprim-sulfamethoxazole adminis-
tration was initiated immediately, and his respiratory symptoms
improved dramatically within a week, along with dissolution of the
interstitial shadow on radiographs. Unfortunately, everolimus was
discontinued even after recovery from PCP owing to intolerable
adverse gastrointestinal effects, including nausea and anorexia. TheFig. 1. Chest radiograph (A) and chest CT (B) on the ﬁrst hospital day. Diffuse ground-glass op
Metastasis to the thoracic wall was also evident (arrow head).patient was referred to the palliative care unit and died of cancer 5
months later.
3. Discussion
Everolimus is a potent immunosuppressant prescribed for
immunocompromised hosts with malignancies and is known to
increase the risk of Pneumocystis jirovecii infections. However, to
our knowledge, there is only 1 case report of PCP associated with
everolimus therapy [6]. As reported in the present case, differen-
tiation of drug-induced ILD and PCP is extremely difﬁcult as they
share several of the clinical ﬁndings described below. This em-
phasizes the risk of overlooking or misdiagnosing PCP as common
everolimus-induced ILD; these errors might result in treatment
delays and a fatal outcome.
3.1. Radiographic ﬁndings
The radiographic manifestations of drug-induced ILD by ever-
olimus change over time. In general, CT patterns can be divided into
4 groups: pattern A (nonspeciﬁc areas of ground-glass attenua-
tion); B (multifocal areas of airspace consolidation); C (patchy
distribution of ground-glass attenuation accompanied by inter-
lobular septal thickening); and D (extensive bilateral ground-glass
attenuation or airspace consolidation with traction bronchiec-
tasis) [6]. The A, B, and C patterns are not speciﬁc to ILD but are
often seen in patients with PCP [7]. In addition, pattern D is difﬁcult
to distinguish from PCP, particularly in patients with underlying
pulmonary diseases such as chronic obstructive pulmonary disease
(COPD), bronchiectasis, and pulmonary ﬁbrosis. The CT ﬁndings in
the present case correspond with pattern A (nonspeciﬁc areas ofacity with an irregular distribution without volume loss is apparent in both lung ﬁelds.
Fig. 2. Chest radiograph on the third hospital day. Despite steroid pulse therapy, the
interstitial shadow expanded rapidly in both lung ﬁelds. BAL was performed from the
right B3b. Trimethoprim-sulfamethoxazole was administered immediately following
this procedure.
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drug-induced ILD and PCP.
3.2. BAL ﬁnding
The cellular pattern of BALF in drug-induced lung toxicity is
classiﬁed into 5 groups: cellular pneumonitis, eosinophilic pneu-
monia, organizing pneumonia, cytotoxic reaction, and diffuse
alveolar damage [8]. The mechanism of everolimus-induced lung
toxicity remains unknown but is thought to be a delayed hyper-
sensitivity reaction [9]. Accordingly, the most characteristic BAL
ﬁnding of everolimus-induced ILD is cellular pneumonitis with
increased lymphocytes. This usually predicts a favorable response
to corticosteroid therapy. The present case revealed a typical
cellular pneumonitis with an increase in total cell number and
lymphocyte dominance as high as 30%. However, lymphocytosis or
eosinophilia in BALF has also been reported in HIV-negative PCP
patients [10]. A recent cohort study demonstrated no signiﬁcant
difference in cell count or differential count in BALF between PCP
and non-PCP patients [11]. Therefore, the cell fractionation pattern
of BALF per sé is not sufﬁcient to exclude PCP.
3.3. Drug-induced lymphocyte stimulation test (DLST)
Of interest, the present case revealed a positive result against
everolimus in DLST of BALF. Everolimus is an immunosuppressant
that inhibits cell proliferation of B- and T-cells. The routine use of
DLST is not recommended except for research purpose, because the
interpretation of its results for immunosuppressive agents is often
complicated, and its value remains controversial [12]. However,
considering the nature of this agent, a false-negative result would
be expectedmore often and in fact has been reported elsewhere [9].
Thus, a positive DLST might indicate a concomitant drug allergy,
although it is not sufﬁcient to exclude the possibility of PCP.
3.4. PCR and b-D glucan
A deﬁnitive diagnosis of PCP is established on the basis of histo-
logical identiﬁcation of Pneumocystis jirovecii organisms in BALF or
TBLB specimens. However, identiﬁcation of the organism innon-AIDS
patients is difﬁcult because of an insufﬁcient number of organisms
[13]. As an alternative, PCR of Pneumocystis jirovecii is a simple and
reliable surrogate marker for direct identiﬁcation of the organism.The sample is obtained simply from sputum or endobronchial
washings and not by a full BALF; further, this test is now also used in
patients with general respiratory distress. Moreover, serum bD
glucan levels are a credible marker for PCP, with a sensitivity of 92%
and speciﬁcity of 86% [13]. The present case was diagnosed conclu-
sively as PCP, primarily on the basis of the PCR ﬁndings in BALF and
the elevated bD glucan levels along with the lack of response to
corticosteroid therapy. The main drawbacks of these laboratory
markers are the time delay in diagnosis, which might help in initia-
tion of appropriate therapy. PCP in non-HIV patients progresses very
rapidly, with treatment delays often resulting in a fatal outcome
[14,15]. Therefore, chemoprevention or prophylactic administration
of trimethoprimesulfamethoxazole are recommended in these pa-
tients, at least until the examination results are obtained.
As mentioned previously, the incidence of everolimus-induced
ILD is exceptionally high with other immunosuppressant and
anticancer drugs. The severity of respiratory toxicity that is induced
by everolimus ranges from very subtle to severe respiratory failure
[15.16]. Most patients are asymptomatic despite the high incidence
of interstitial shadows on chest CT [15]. Themanagement algorithm
for everolimus-induced ILD is different from that of other drug-
induced ILDs. For example, discontinuation of everolimus is not
necessary for asymptomatic patients (CACTE Grade1) or those with
mild radiographic ﬁndings. Further, patients with mild symptoms
(CACTE Grade 2) can be rechallenged with everolimus soon after
recovery following tentative drug discontinuation. Thus, there is
considerable risk of overlooking PCP or managing the condition
with corticosteroids as drug-induced ILD; these errors might
exacerbate the respiratory distress.
Because everolimus is now used to treat patients with various
types of cancer and backgrounds, this manifestation of PCP might
increase in the future. Thus, it is important to make all possible
efforts to survey and monitor opportunistic infections of PCP
whenever everolimus is used and to initiate therapy at appropriate
times throughout the treatment course.Conﬂict of interest
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